快速改善型ARDS与持续性ARDS在临床和生物学上的差异
该研究分析两个中心(一个三级医疗中心和一个城市安全网医院)前瞻性观察队列中215例符合柏林标准且气管插管的ARDS患者,按既往研究定义快速改善型ARDS(RIARDS):诊断后第2天PaO2:FiO2>300或SpO2:FiO2>315,或第2天至第4天无气管插管自主呼吸。RIARDS占21%,其医院死亡率13% vs 持续性ARDS 57%(P<0.001),无ICU天数中位数24 vs 0(P<0.001);血浆IL-6、IL-8和PAI-1水平显著更低,低炎症表型占比78% vs 51%(P=0.001)。作者认为识别并排除RIARDS可能改善临床试验的预后和预测富集。
要点
- RIARDS定义为诊断后第2天PaO2:FiO2>300或SpO2:FiO2>315,或第2天至第4天无气管插管自主呼吸。
- RIARDS占全部ARDS的21%,医院死亡率13% vs 持续性ARDS 57%(P<0.001)。
- RIARDS患者无ICU天数中位数24 vs 持续性ARDS 0(P<0.001)。
- RIARDS患者血浆IL-6、IL-8和PAI-1水平显著低于持续性ARDS。
- 低炎症表型在RIARDS中占78% vs 持续性ARDS 51%(P=0.001)。
适用人群与场景
- 两个中心(一个三级医疗中心和一个城市安全网医院)前瞻性观察队列中215例符合柏林标准且气管插管的ARDS患者。
诊断标准与关键阈值
- RIARDS定义:诊断后第2天满足以下任一条件:(i)PaO2:FiO2>300;(ii)SpO2:FiO2>315;(iii)第2天至第4天无气管插管自主呼吸。
研究设计与关键结果
- 研究类型:前瞻性观察队列,两个中心,样本量215例符合柏林标准且气管插管的ARDS患者。
- RIARDS占全部ARDS参与者的21%。
- RIARDS患者医院死亡率13% vs 持续性ARDS 57%(P<0.001)。
- RIARDS患者无ICU天数中位数24 vs 持续性ARDS 0(P<0.001)。
- RIARDS患者血浆IL-6、IL-8和PAI-1水平显著低于持续性ARDS。
- 低炎症表型在RIARDS中占78% vs 持续性ARDS 51%(P=0.001)。
证据类型、等级与局限
- 证据类型:前瞻性观察队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,识别并排除RIARDS可能改善临床试验的预后和预测富集。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Rapidly improving acute respiratory distress syndrome (RIARDS) is an increasingly appreciated subgroup of ARDS in which hypoxemia improves within 24 h after initiation of mechanical ventilation. Detailed clinical and biological features of RIARDS have not been clearly defined, and it is unknown whether RIARDS is associated with the hypoinflammatory or hyperinflammatory phenotype of ARDS. The purpose of this study was to define the clinical and biological features of RIARDS and its association with inflammatory subphenotypes.
METHODS: We analyzed data from 215 patients who met Berlin criteria for ARDS (endotracheally intubated) and were enrolled in a prospective observational cohort conducted at two sites, one tertiary care center and one urban safety net hospital. RIARDS was defined according to previous studies as improvement of hypoxemia defined as (i) PaO2:FiO2 > 300 or (ii) SpO2: FiO2 > 315 on the day following diagnosis of ARDS (day 2) or (iii) unassisted breathing by day 2 and for the next 48 h (defined as absence of endotracheal intubation on day 2 through day 4). Plasma biomarkers were measured on samples collected on the day of study enrollment, and ARDS phenotypes were allocated as previously described.
RESULTS: RIARDS accounted for 21% of all ARDS participants. Patients with RIARDS had better clinical outcomes compared to those with persistent ARDS, with lower hospital mortality (13% vs. 57%; p value < 0.001) and more ICU-free days (median 24 vs. 0; p value < 0.001). Plasma levels of interleukin-6, interleukin-8, and plasminogen activator inhibitor-1 were significantly lower among patients with RIARDS. The hypoinflammatory phenotype of ARDS was more common among patients with RIARDS (78% vs. 51% in persistent ARDS; p value = 0.001).
CONCLUSIONS: This study identifies a high prevalence of RIARDS in a multicenter observational cohort and confirms the more benign clinical course of these patients. We report the novel finding that RIARDS is characterized by lower concentrations of plasma biomarkers of inflammation compared to persistent ARDS, and that hypoinflammatory ARDS is more prevalent among patients with RIARDS. Identification and exclusion of RIARDS could potentially improve prognostic and predictive enrichment in clinical trials.
参考来源
- Valda Toro PL, Willmore A, Wu NE, et al. Rapidly improving ARDS differs clinically and biologically from persistent ARDS. Crit Care. 2024. PMID: 38649920. doi:10.1186/s13054-024-04883-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。